Peter Ro, PETER, RO

Peter Ro practices at Surgery Center Palo Alto in Palo Alto, California.

Peter Ro's NPI, 1376879007, was assigned on October 30, 2009. Peter Ro holds California license A140454.

Peter Ro's primary practice is Surgery Center Palo Alto, at 795 El Camino Real, Palo Alto, CA 94301. The practice phone is (650) 324-1832.

Peter Ro's primary practice is Surgery Center Palo Alto in Palo Alto, California. Peter Ro is also affiliated with Mills-Peninsula Medical Center. The medical group on file is Palo Alto Foundation Medical Group. Dmand AI also links Peter Ro to 1 more group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Peter Ro practices, 4 sites in all. Vendor and product names are available with a free account.

Family medicine is Peter Ro's primary specialty in the NPI Registry, under taxonomy code 207Q00000X. Peter Ro is licensed in California.

CMS data shows 433 Medicare services from Peter Ro across 8 procedure codes in 2024, for 156 Medicare patients. Medicare paid $45,913 for them. Every service was in an office.

CMS counts 156 Medicare patients who saw Peter Ro in 2024. The largest group is 65 to 74, with 72 patients. 69% of them have high cholesterol, and 53% have high blood pressure. Their average risk score is 0.80, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Peter Ro's median patient age at 55, with 47% women.

In 2024, Peter Ro wrote 1,668 Medicare Part D claims for 185 patients. 91% of them were for generic drugs. CMS names the drug for 1,371 of them, across 39 drugs with 11 or more claims each, at $68,442 in total drug cost. In 2023, CMS named 1,178 claims across 34 drugs.

Peter Ro accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Peter Ro as offering telehealth.

CMS Open Payments shows 1 general payment to Peter Ro from 1 drug or device company in 2017. Food and beverage make up the largest share, 100% of the total. Merck Sharp & Dohme Corporation paid the most, $21.